Evidence map›Paper›PMID 40746429›Full record

ArticleFrontiers in artificial intelligence2025

A reliable approach for identifying acute lymphoblastic leukemia in microscopic imaging.

Mimosette Makem, Levente Tamas, Lucian Bușoniu

Abstract read
In one paragraph

Article in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mimosette MakemSignal, Image, and Systems Laboratory, Department of Medical and Biomedical Engineering, HTTTC EBOLOWA, University of Ebolowa, Ebolowa, Cameroon.
Levente TamasDepartment of Automation, Technical University of Cluj-Napoca, Cluj-Napoca, Romania.
Lucian BușoniuDepartment of Automation, Technical University of Cluj-Napoca, Cluj-Napoca, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukemia is a deadly disease, and the patient's recovery rate is very dependent on early diagnosis. However, its diagnosis under the microscope is tedious and time-consuming. The advancement of deep convolutional neural networks (CNNs) in image classification has enabled new techniques in automated disease detection systems. These systems serve as valuable support and secondary opinion resources for laboratory technicians and hematologists when diagnosing leukemia through microscopic examination. In this study, we deployed a pre-trained CNN model (MobileNet) that has a small size and low complexity, making it suitable for mobile applications and embedded systems. We used the L1 regularization method and a novel dataset balancing approach, which incorporates HSV color transformation, saturation elimination, Gaussian noise addition, and several established augmentation techniques, to prevent model overfitting. The proposed model attained an accuracy of 95.33% and an F1 score of 0.95 when evaluated on the held-out test set extracted from the C_NMC_2019 public dataset. We also evaluated the proposed model by adding zero-mean Gaussian noise to the test images. The experimental results indicate that the proposed model is both efficient and robust, even when subjected to additional Gaussian noise. The comparison of the proposed MobileNet_M model's results with those of ALNet and various other existing models on the same dataset underscores its superior efficacy. The code is available for reproducing the experimental results at https://tamaslevente.github.io/ALLM/.

Indexed as

CNNdata augmentationdisease detectionimage processingleukemia classification

Identifiers

PMID40746429
PMCPMC12310707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.